Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. - Wikidata - awgldk - TriplyDB

Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver.

Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver.

http://www.wikidata.org/entity/Q46670089

about

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis PPARs and the cardiovascular system The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure Effects of PPARalpha on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle?Full-length adiponectin attenuates insulin signaling and inhibits insulin-stimulated amino Acid transport in human primary trophoblast cells Crif1 deficiency reduces adipose OXPHOS capacity and triggers inflammation and insulin resistance in mice Cardiac-specific ablation of ARNT leads to lipotoxicity and cardiomyopathy.New insights into insulin resistance in the diabetic heart.Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle.Mitochondria and Oxidative Stress in the Cardiorenal Metabolic Syndrome.Fenofibrate inhibited the differentiation of T helper 17 cells in vitro.Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion.Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure Protective Effect of Peroxisome Proliferator-Activated Receptor α Activation against Cardiac Ischemia-Reperfusion Injury Is Related to Upregulation of Uncoupling Protein-3 The PPARalpha-PGC-1alpha Axis Controls Cardiac Energy Metabolism in Healthy and Diseased Myocardium.Should We Use PPAR Agonists to Reduce Cardiovascular Risk?Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes.Perturbations in the gene regulatory pathways controlling mitochondrial energy production in the failing heart.Insulin resistance: metabolic mechanisms and consequences in the heart.Myocardial AKT: the omnipresent nexus.Testosterone Replacement Modulates Cardiac Metabolic Remodeling after Myocardial Infarction by Upregulating PPARα.Type 2 diabetes, mitochondrial biology and the heart.Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle.Lipoprotein lipase activity is required for cardiac lipid droplet production.PPARs: diverse regulators in energy metabolism and metabolic diseases.Peroxisome proliferator activated receptor-alpha (PPARα) and PPAR gamma coactivator-1alpha (PGC-1α) regulation of cardiac metabolism in diabetes.Lipotoxicity and cardiac dysfunction in mammals and Drosophila.Sphingolipids, lipotoxic cardiomyopathy, and cardiac failure.Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients Gliptins and cardiometabolic risk.Rosiglitazone-loaded nanospheres for modulating macrophage-specific inflammation in obesity.A novel high-throughput screening assay for putative antidiabetic agents through PPARalpha interactions.Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPARalpha.Akt2 deficiency promotes cardiac induction of Rab4a and myocardial β-adrenergic hypersensitivity.Too much or not enough of a good thing? Cardiac glucolipotoxicity versus lipoprotection.Loss of stearoyl-CoA desaturase 1 inhibits fatty acid oxidation and increases glucose utilization in the heart.Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart.Inhibition of mammalian target of rapamycin protects against reperfusion injury in diabetic heart through STAT3 signaling.Chronic maternal infusion of full-length adiponectin in pregnant mice down-regulates placental amino acid transporter activity and expression and decreases fetal growth.Changes in myocardial mechanics in patients with obesity following major weight loss after bariatric surgery.

P2860

Q24541529-44D115EF-4A61-47DE-A5F9-02ED27DADE50 Q24642728-27C8140E-8BE7-40C8-8972-D5240770AD8C Q28082343-EDE7BCCE-F494-4A7C-88A6-AF7047F906AB Q30353176-6FB278CE-4030-4818-84E4-1457B6BD764E Q33803438-107D446D-DCAA-41CF-893C-CEB2F2B7BAA1 Q34629224-7247ADD2-0B51-43AB-9937-285262A02BAE Q35140057-F15C9A8C-788A-4578-8B9D-BAF264CD1156 Q35243945-7B5789FF-D57F-4A42-9445-4B49A1FD4012 Q35636191-9BD68B00-9587-4C5D-BEA3-1D8555B5AF9E Q35771152-E884ABD9-C4EB-44FB-9C94-F2A467C3BCE1 Q35976043-8BCC8CDB-1570-4FD5-92F7-8A163DC45CA4 Q36072203-DF3CD204-9FE5-4353-8358-637F26D5555F Q36099739-2043D695-AFD3-400C-94F2-6A7219AD2936 Q36298248-7D821A14-AF11-47FB-B29F-1F94951D83D9 Q36387538-75F402EF-DA3C-4DE3-807E-F7981C124DFE Q36426768-82661480-558E-4400-A50E-35CDCF3F4E71 Q36446970-8359F0AB-A796-45AD-BD2B-08BD8B844E18 Q36547048-A7A42498-7573-4B1E-BCED-02DD38E66043 Q36605039-909D7C2F-233D-4602-9A42-6323EA6EE06E Q36821424-0267AF99-DBF7-4848-BCC4-A6634FF33989 Q36908289-72F7DACA-BCD9-4FF9-83A8-A84F76E781FF Q37054050-2485DC7E-64DD-4FF7-88D2-77745EAC62B5 Q37195072-B5EBC6F0-4D05-4BB0-B060-9A647FCC5E0E Q37400702-0A3E1AFD-1EA4-4CB4-9FAB-1B7F5A4B244F Q37665433-B754E5B8-17CA-4332-97D4-12CA99BFEF73 Q37681306-CDD67038-3C40-47C3-875E-29C6227F38FB Q37834354-EAAC9E7E-EA34-4471-908F-6115A4B74B7D Q37919531-B74F659F-4F5A-4969-A05A-DF43CD6E650A Q38045551-F71E1FA0-A66A-4DDA-B8C6-F7F737645F90 Q38620945-FF785019-8A8B-4B50-8FC1-C022B8ECD7B3 Q39136593-E832F97C-AEE5-49BC-B744-C051695B6404 Q41844457-637EAA44-E347-4316-9495-06C5B28BF746 Q41917508-44D36466-EBF6-4653-90A5-293BEE81EBDB Q41969432-70AA1534-3876-4FFB-B692-AEBA9500D60B Q42161575-25C38098-E1BA-43FC-99FF-A766EF3A607D Q42521891-C3B5FE92-0DD2-4F8B-8253-CF915EFD5190 Q42593363-1B1E5DC2-FF92-46F2-BEF1-10453228C921 Q45012762-94309655-A628-41E3-9422-F4B5BEE1BCBA Q45070271-0BC64366-4725-48FC-9A3E-F68431D8DE3A Q45384322-5EBF251F-BE35-42D5-929C-692E63BC0464

P2860

Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver.

http://www.wikidata.org/entity/Q46670089

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Cardiac-specific overexpressio ...... resistance in heart and liver.

@en

Cardiac-specific overexpressio ...... resistance in heart and liver.

@nl

type

label

Cardiac-specific overexpressio ...... resistance in heart and liver.

@en

Cardiac-specific overexpressio ...... resistance in heart and liver.

@nl

prefLabel

Cardiac-specific overexpressio ...... resistance in heart and liver.

@en

Cardiac-specific overexpressio ...... resistance in heart and liver.

@nl

P1433

Q46670089-3F5808C7-AEFB-4E42-AB0B-838C36A44E4F

P1476

Q46670089-6F2B01E9-05F3-4A10-ABE9-65E253B9D917

P2093

Q46670089-061C4AFA-E62E-4195-9F55-7D59945D5EA6

Q46670089-15894FBE-8D6B-40D1-BF60-C3B023FCF191

Q46670089-2EF7BF20-FF04-49AA-A3B4-1BDAFDA8368E

Q46670089-3C4198E2-1016-4AFB-93FC-DEB25382F85D

Q46670089-4935F4AB-A3B9-46D7-92FE-A6F27AC6A9DA

Q46670089-4D7F9C44-5209-465B-B612-592630C40F87

Q46670089-5CE05576-A90F-4BF3-9BD8-38C063C8E638

Q46670089-716DEEE8-CB03-4169-BF9D-8B4C5661209C

Q46670089-750E6F3A-3FF4-4663-8729-60E5C3FB8673

Q46670089-7BD33F06-C672-4115-AC6F-AA86F43361A9

P304

Q46670089-78B9E3C1-C199-4F40-ABEB-7C0D237D4160

P31

Q46670089-9A108D80-338C-42DE-9181-6467D52C71EC

P356

Q46670089-6CF98738-40C3-4DCA-912D-BFCCA94C97AE

P407

Q46670089-9C22371D-1DBB-4EBF-B111-7EDB3446EE02

P433

Q46670089-84E34E6B-93E1-476D-9B0C-AB7BAC11678D

P478

Q46670089-9C5E51E6-B057-47AC-819B-58850183F030

P577

Q46670089-F370AAA6-2FF7-47FD-8E62-8DB1D724FEF2

P5875

Q46670089-695FBFD5-B81A-4242-A120-6958F0047745

P698

Q46670089-FFF38E61-D22E-4C9D-B2BF-17ED7D3BB277

P921

Q46670089-81554609-4714-44EB-9045-B09784C97BDC

Q46670089-D7BCF30E-451B-4AD0-89A8-BFA06DD49405

P356

DIABETES.54.9.2514

P1433

P1476

Cardiac-specific overexpressio ...... resistance in heart and liver.

@en

P2093

Anton M Bennett

http://www.w3.org/2001/XMLSchema#string

April Kalinowski

http://www.w3.org/2001/XMLSchema#string

Beverly Rothermel

http://www.w3.org/2001/XMLSchema#string

Brian N Finck

http://www.w3.org/2001/XMLSchema#string

Cheryl Danton

http://www.w3.org/2001/XMLSchema#string

Daniel P Kelly

http://www.w3.org/2001/XMLSchema#string

Eun-Gyoung Hong

http://www.w3.org/2001/XMLSchema#string

Gary W Cline

http://www.w3.org/2001/XMLSchema#string

Hyo-Jeong Kim

http://www.w3.org/2001/XMLSchema#string

Jason K Kim

http://www.w3.org/2001/XMLSchema#string

P304

2514-2524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DIABETES.54.9.2514

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7638024

http://www.w3.org/2001/XMLSchema#string

P698

16123338

http://www.w3.org/2001/XMLSchema#string

P921